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Uneven Development
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Over recent years, there has been widespreadacknowledgment of the lack of resources avail-
able to satisfy the growing demand for health and
health care. This awareness has led to a global
increase in the use of cost-effectiveness analysis to
support decisions regarding service provision. How-
ever, identifying and issuing guidance regarding the
use of cost-effective health technologies does not, in
itself, lead to cost-effective service provision. This
requires that practitioners implement the guidance.
The implicit assumption within analyses is that
practitioners immediately alter their practice to
implement a technology once it is identified as cost-
effective. In reality, implementation is rarely perfect,
with some practitioners maintaining nonoptimal
preguidance practice. The reasons for nonimplemen-
tation are various and include practitioners facing
different incentives or possessing different perspec-
tives on cost-effectiveness, the existence of imperfect
clinical governance, and an asymmetry of informa-
tion between policy makers and local decision
makers. Irrespective of the cause, less than perfect
implementation reduces the efficiency of the health
care system in terms of the health that can be gener-
ated subject to a given budget constraint. As a result,
Aim. In a budget-constrained health care system, the deci-
sion to invest in strategies to improve the implementation
of cost-effective technologies must be made alongside deci-
sions regarding investment in the technologies themselves
and investment in further research. This article presents
a single, unified framework that simultaneously addresses
the problem of allocating funds between these separate
but linked activities. Methods. The framework presents a
simple 4-state world where both information and imple-
mentation can be either at the current level or ‘‘perfect.’’
Through this framework, it is possible to determine the
maximum return to further research and an upper bound
on the value of adopting implementation strategies. The
framework is illustrated through case studies of health
care technologies selected from those previously consid-
ered by the UK National Institute for Health and Clinical
Excellence (NICE). Results. Through the case studies, sev-
eral key factors that influence the expected values of
perfect information and perfect implementation are identi-
fied. These factors include the maximum acceptable cost-
effectiveness ratio, the level of uncertainty surrounding the
adoption decision, the expected net benefits associated
with the technologies, the current level of implementation,
and the size of the eligible population. Conclusions. Pre-
vious methods for valuing implementation strategies have
not distinguished the value of efficacy research and the
value of strategies to change the level of implementation.
This framework demonstrates that the value of informa-
tion and the value of implementation can be examined
separately but simultaneously in a single framework. This
can usefully inform policy decisions about investment in
health care services, further research, and adopting imple-
mentation strategies that are likely to differ between tech-
nologies.
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there has been growing interest in strategies to
improve implementation of technologies.
In the United Kingdom, the National Institute
for Health and Clinical Excellence (NICE) has been
issuing guidance regarding the use of health tech-
nologies since its inception in 1999. However, NICE
has no power to enforce adherence to guidance, and
a recent study has shown varying degrees of success
regarding implementation.1 In response to variation
in and uncertainty about the implementation of gui-
dance, NICE charged recently appointed an imple-
mentation systems director task with the of creating
a work plan to ‘‘enable the NHS [National Health
Service] to implement NICE guidance.’’2
There are 3 main tasks for decision makers such
as NICE: first, to identify and issue guidance about
cost-effective health technologies; second, to issue
guidance regarding the need for further research
concerning health technologies; and third, to pro-
mote implementation of guidance and uptake of
cost-effective technologies. In a budget-constrained
health care system, such as the UK National Health
Service (NHS), there is a single ‘‘pot’’ of resources
from which funds must be found to support these
activities. There is an established literature con-
cerning the use of cost-effectiveness analysis to
support decisions regarding service provision.3-6
Policy decisions regarding investment in future
research and the collection of further information
can be supported by value-of-information (VOI)
analysis.7-14 These techniques provide a monetary
value for the potential benefits of research that can
be compared with the costs to determine if further
research is worthwhile. However, it is less clear
how to evaluate and support decisions regarding
investment in strategies to change implementation.
The studies that have examined interventions to
change implementation have tended to concentrate
on the cost-effectiveness of specific policies rather
than identifying the potential value of investing in
implementation policies.15-17
This article proposes a single, unified framework
to address the problem of allocating funds between
these separate but linked activities. The article builds
on an established framework that unifies decisions
concerning investment in research and service provi-
sion to ensure that investment in research is subject
to the same evaluation of efficiency as investment in
health care provision.11, 18, 19 The proposed frame-
work separately but simultaneously establishes cost-
effective service provision and the maximum returns
to investment in further research (through the expec-
ted value of perfect information) and implementation
activities (through the expected value of perfect
implementation). These upper bounds provide neces-
sary conditions for conducting further research and/
or implementation strategies and should be compared
to the costs of these policies to determine whether
they are potentially worthwhile. Identifying whether
specific investments in research and/or implementa-
tion strategies are worthwhile, per se, will require a
sufficient condition that identifies the benefits and
costs associated with the specific policy.
The framework is distinct from ‘‘payback’’
methodologies that attempt to measure the cost-
effectiveness, or value, of further research through
an assessment of the likely impact of the research on
clinical practice.20-26 In these approaches, trials are
seen as ‘‘an investment in information which will
contribute to the . . . extent of product adoption thro-
ugh the strength and relevance of the information
they produce.’’20ðp617Þ As such, these approaches
do not distinguish the value of research to reduce
uncertainty from the value of changing clinical prac-
tice. Valuable though the impact of research on
behavior is, it is not the primary reason for conduct-
ing clinical research, and it is certainly not the
only—or necessarily a cost-effective way—to change
clinical practice. The failure of payback methods to
distinguish the value of reducing uncertainty thr-
ough research from the value of altering clinical
practice means that they provide no information
with respect to the allocation of funds between these
2 separate, but related, activities.
This article starts with an outline of the proposed
framework. The framework is then illustrated through
a series of case studies, each of which involves a tech-
nology previously considered by NICE. The article
concludes with a discussion of the key factors that
could affect the valuations and influence the alloca-
tion of resources, as identified through the case stu-
dies, and some suggestions for the future direction of
this research.
FRAMEWORK
The proposed framework builds on Bayesian VOI
analysis to simultaneously address decisions concer-
ning investment in research and service provision.
This established framework is expanded to incorpo-
rate decisions regarding investment in implementa-
tion activities, through an assessment of the expected
value of implementation strategies, in a way analo-
gous to the use of VOI analysis to determine the
expected value of information.
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The issues of interest are a) the level of informa-
tion available about a particular health technology
and b) the level of implementation of the health
technology. For the moment, the framework is
restricted to consider 2 circumstances with respect
to the level of information and implementation:
1) the current level and 2) the perfect level. Thus,
the framework represents a simple 4-state world that
can be illustrated through a 2× 2 matrix (see
Table 1). The implications of this simplification are
examined in the Discussion section along with sug-
gestions for expanding the framework beyond this
simple 4-state world.
The 2 columns represent the state of the world
with regard to the level of information available
about the technology (perfect or current). The 2 rows
represent the state of the world with regard to the
implementation of the technology (perfect or cur-
rent). The level of implementation is denoted by the
proportion of the eligible patient base that receives
the technology (r). Perfect implementation requires
that r= 1 when the technology is determined as the
most cost-effective (i.e., generates a positive incre-
mental net benefit or maximizes net benefit) and
r= 0 otherwise. The current level of implementa-
tion can, however, take any value between 0 and 1
depending on the uptake of the technology.
Each entry within the matrix represents the
expected value of a decision made in that state of
the world, measured in terms of net monetary bene-
fits. Thus, cell A represents the expected value of a
decision made on the basis of current information
with the current level of implementation, cell B
represents the expected value of a decision made on
the basis of perfect information with the current
level of implementation, cell C represents the
expected value of a decision made on the basis of
current information with perfect implementation,
and cell D represents the expected value of a deci-
sion made on the basis of perfect information with
perfect implementation. The expected value of the
decision made on the basis of a perfect state (with
regard to information and/or implementation) must
be at least as great as the expected value of the deci-
sion made on the basis of a current state. Therefore,
B ≥ A, C ≥ A, D ≥ C, D ≥ B, and D ≥ A.
Initially, a simplifying assumption is made—that
information alone has no effect on the current level
of implementation, which is instead only influenced
as a result of direct implementation strategies (i.e.,
that there is no relationship between information
and implementation). Under this assumption, cell
B= cell A. The effect of relaxing this assumption is
investigated within a sensitivity analysis.
Through comparison and subtraction of the respec-
tive expected values, the simple framework can be
used to determine the value of further research that
shifts the state of information from the current level
to the perfect level (perfect information), as well as
the value of implementation strategies that shift the
level of implementation from current to perfect (per-
fect implementation). It is through this process that
the expected value of perfect information and the
expected value of perfect implementation are identi-
fied. These values establish a maximum return on
investment within the area (implementation or infor-
mation) and provide a necessary condition for deter-
mining whether such investments are potentially
worthwhile.
Expected Value of Perfect Information (EVPI)
Value of information analysis involves establish-
ing the difference between the expected value of a
decision made on the basis of existing evidence and,
following the collection of further information, the
expected value of a decision made on the basis of
the new evidence.7 Value of information analysis
implicitly assumes that there is perfect implementa-
tion in both the current and the perfect information
state.
The expected value of perfect information (EVPI)
is calculated as the difference between a position of
perfect information about the technology (no uncer-
tainty) and the current information position. In
terms of the 2× 2 matrix, the EVPI is simply the dif-
ference between cell D and cell C.
The information provided by research is a public
good. As such, the societal value of research should
be calculated across the population of future patients
for whom this decision is relevant. It is this popula-
tion EVPI that provides a measure of the maximum
Table 1 2× 2 Matrix for Determining the
Expected Value of Perfect
Information, Expected Value of Perfect
Implementation, and Expected
Value of Perfection
Information
Implementation Current Perfect
Current A B
Perfect C D
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return to further research, providing a necessary con-
dition for determining whether further research is
potentially worthwhile, under the assumption that
provision is perfectly dictated by the expected value
of the decision.
‘‘Realizable’’ EVPI
Given that implementation is rarely perfect, the
‘‘realizable’’ EVPI identifies the expected value of
research that is realizable without actively undertak-
ing strategies to change implementation. In the 2× 2
matrix, this is simply the difference between cell B
and cell A. The simplifying assumption, that there
is no relationship between information and imple-
mentation, results in values for realizable EVPI of 0.
This assumption is relaxed within the sensitivity
analysis.
Expected Value of Perfect Implementation (EVPIM)
Value of implementation analysis involves estab-
lishing the difference between the expected value
of a decision with the current level of implementa-
tion and the expected value of the decision with a
revised level of implementation.
The expected value of perfect implementation
(EVPIM) is calculated as the difference between the
expected value of a decision that is implemented
perfectly (r is either 0 or 1 as dictated by the cost-
effectiveness of the technology) and the expected
value of the decision with implementation at its cur-
rent level. Where the current level of implementa-
tion is ‘‘perfect,’’ there will be no value in strategies
to change implementation. The population EVPIM
gives a measure of the maximum return to strategies
to change implementation and provides a necessary
condition for determining whether such strategies
are potentially worthwhile.
The calculation of the EVPIM requires no assump-
tion about the level of information on which the
decision is based and can be based on either infor-
mation position. In terms of the 2× 2 matrix, the
EVPIM based on the current level of information is
simply the difference between cell C and cell A. The
EVPIM based on perfect information is simply the
difference between cell D and cell B in the matrix.
Expected Value of ‘‘Perfection’’ (EVP)
Finally, a comparison of the difference in the
expected value of the decision made in the perfect
state, with respect to information and implementa-
tion, and that made in the current state provides the
decision maker with the expected value of ‘‘perfec-
tion’’ (EVP) in terms of information and implemen-
tation. The population EVP provides a measure of
the maximum return to resources expended on
research and implementation strategies. In terms of
the 2× 2 matrix, the EVP is simply the difference
between cell D and cell A.
CASE STUDIES
The simple 4-state framework is illustrated
through the use of 3 case studies that were selected
from those recently considered by NICE.27-29 The
case studies examine the use of orlistat for the treat-
ment of obesity (NICE publication no. 22),29 the use
of zanamivir for the treatment of influenza (NICE
publication no. 15),28 and the prophylactic extrac-
tion of wisdom teeth (NICE publication no. 1).27 For
each of the case studies, a simple, stylized decision
model was constructed to represent the decision
problem. The parameter estimates used within the
stylized models were publicly available in either
the assessment reports or guidance documents. In
each case, the estimates of effectiveness were based
on the reported meta-analysis of the randomized con-
trolled trial (RCT) evidence, but other key inputs,
such as cost, baseline risks, health state utilities, and/
or other relevant epidemiological variables, were
based on other sources (observational studies and, in
some cases, informed judgment). The population size
and the estimate of the current level of implementation
were also taken from public sources (where possi-
ble, these were the assessment reports and guidance
documents).
It should be stressed that the case studies are used
here purely as a vehicle to demonstrate the proposed
framework. Table 2 contains further details of the 3
case studies.
RESULTS
Each of the case studies included uncertain para-
meters (y). Probabilistic sensitivity analysis was con-
ducted using Monte Carlo simulation and provided
the joint distributions of costs, quality-adjusted life
years (QALYs), and net benefits (NB) associated with
each of the alternative technologies (j= 1, . . ., J). The
expected value of the decisions in each of the 4
states of the world (cells A, B, C, and D in Table 1)
was calculated directly from the simulated output:
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Cell A=
XJ
j= 1
rcj :EyNBðj, yÞ,
Cell B=Ey
XJ
j= 1
rpj :NBðj, yÞ,
Cell C= maxj EyNBðj, yÞ,
Cell D=Eymaxj NBðj, yÞ;
where
rcj = probability of implementing technology j with
current information,
rpj = probability of implementing technology j with
perfect information,
XJ
j= 1
rcj = 1,
XJ
j= 1
rpj =1:
Each iteration of the simulation represents a pos-
sible resolution of the uncertain parameters (y).
Given current information, the cost-effective tech-
nology is alterative j, which provides the maximum
expected net benefit (e.g., maxj EyNBðj, y) in cell C).
With perfect information, the alterative that pro-
vides the maximum NB for each resolution of the
uncertain parameters can be chosen (maxj NBðj, yÞ).
The expected net benefit with perfect information is
then the expectation of these maximum net benefits
over all the resolutions of y (e.g., Eymaxj NBðj, y) in
cell D). However, if implementation is not perfect
(i.e., the j that maximized net benefit is not always
chosen), then the expected net benefits are a weighted
average of the net benefits of each alternative, where
the weights are the probability of implementing each
technology (rcj with current information in cell A and
rpj with perfect information in cell B).
Table 3 presents the results for the 3 case studies,
detailing the incremental cost-effectiveness ratio
associated with the technology, the estimate of the
current level of implementation, and the expected
value of perfect information, perfect implementa-
tion, and ‘‘perfection’’ in millions for the estimated
eligible population. The results for each case study,
including the individual elements of the 2× 2
matrix, are detailed below. All values are based on a
maximum acceptable cost-effectiveness ratio (l) of
30,000 per QALY.
Orlistat
The NICE guidance recommended that orlistat be
adopted for patients with a body mass index in
excess of 30, with the requirement that patients lose
5% of their body weight at 3 months and 10% at 6
months for continued treatment.29 The estimated
population eligible for treatment was 22,000, with
an annual incident population of 11,000 and an esti-
mated 11,000 patients receiving treatment. The cur-
rent level of implementation was 0.504, and the total
eligible population (discounted over 8 years) was
approximately 83,000. The analysis of the stylized
model calculated the incremental cost-effectiveness
ratio associated with orlistat to be 21,267 per QALY
(Table 3). Given a cost-effectiveness threshold of
30,000 per QALY, orlistat was cost-effective given
the information available.
Table 2 Summary of the Case Studies
Technology Orlistat: Zanamivir: Wisdom Teeth:
Obesity Influenza Prophylactic Extraction
of Wisdom Teeth
Publication No. 22 No. 15 No. 1
Guidance Adopt for body mass index > 30
Must lose 5% at 3 months
and 10% at 6 months
Adopt for high risk when
influenza is circulating
Reject
Evidence RCTs, n > 1500 2 CEA RCTs, n > 1250 4 CEA 1 RCT, n<300 4 CEA
Estimate of ICER 10,400–46,000 per QALY 5000–28,000 per QALY Dominated
Population Inc 11,000 End 97,000 Epi 497,000 Inc 11,000
Review 02/04 06/02 03/03
RCT, randomized controlled trial; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; CEA, cost-effectiveness analysis.
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Table 4 presents the 2× 2 matrix for orlistat. The
expected value of the decision made purely on the
basis of this current information was estimated to be
163 (cell C), whereas the expected value of the
decision made on the basis of perfect information
was estimated to be 187 (cell D). The expected
value of perfect information was 24 per decision
(cell D – cell C), giving an EVPI of 2 million for the
eligible population. With the current implementa-
tion level (rc) of 0.504, the realizable expected value
of the decision made on the basis of current informa-
tion was reduced to 82 (cell A). The expected value
of perfect implementation, based on the current
level of information, was 81 per decision (cell C –
cell A), giving an EVPIM of 6:8 million for the eligi-
ble population. The expected value of ‘‘perfection’’
was calculated to be 105 per decision (cell D – cell
A), 8:7 million for the eligible population.
Given the simplifying assumption that the level of
implementation does not change on the basis of
information alone (rc= rp), the expected value of the
decision made on the basis of perfect information
(cell B) was equivalent to the expected value of the
decision made on the basis of current information
(cell A) at 82. Thus, the realizable EVPI (cell B –
cell A) was 0.
Zanamivir
The NICE guidance recommended that zanamivir
be adopted for high-risk patients when influenza
was circulating.28 The estimated annual popula-
tion eligible for treatment was 136,000 (based on
an endemic population of 97,000 with an epidemic
population of 487,000 occurring every 10 years).
With an estimated 458 patients receiving treatment
in 2000–2001, the current level of implementation
was 0.0034, and the total eligible population (dis-
counted over 8 years) was approximately 895,000.
The analysis of the stylized model calculated the
incremental cost-effectiveness ratio associated with
zanamivir to be 22,739 per QALY (Table 3). Given a
cost-effectiveness threshold of 30,000 per QALY,
zanamivir was cost-effective given the information
available.
Table 5 presents the 2× 2 matrix for zanamivir.
The expected value of the decision made purely on
the basis of this current information was estimated
to be 7 (cell C), whereas the expected value of the
decision made on the basis of perfect information
was estimated to be 14 (cell D). The expected value
of perfect information was 6 per decision, 5:6 mil-
lion for the eligible population. With the current
implementation level (rc) of 0.0034, the realizable
expected value of the decision made on the basis of
current information was 0:02 (cell A). The expected
value of perfect implementation, based on the cur-
rent level of information, was 7 per decision, 6:6
million for the eligible population. The expected
value of ‘‘perfection’’ was calculated to be 14 per
decision, 12:1 million for the eligible population.
Wisdom Teeth
The NICE guidance recommended that prophy-
lactic extraction of wisdom teeth should not be
undertaken.27 The annual incident population with
disease-free molars was estimated to be 11,000, for
whom 80% received (inappropriate) extraction of
wisdom teeth (rc= 0:2). The total eligible popula-
tion (discounted over 8 years) was approximately
72,000. The analysis of the stylized model showed
that a policy of the prophylactic extraction of wis-
dom teeth was dominated by a policy of no prophy-
lactic extraction (Table 3), with very little uncertainty
surrounding the decision (not shown).
Table 6 presents the 2× 2 matrix for the prophy-
lactic extraction of wisdom teeth. The expected
Table 3 Expected Value of Perfect Information (EVPI), Expected Value of Perfect
Implementation (EVPIM), and Expected Value of ‘‘Perfection’’ (EVP)
ICER ρ Popn EVPI (in  Millions) EVPIM (in  Millions) EVP (in  Millions)
Orlistat 21,267 0.504 83,406 2.0 6.8 8.7
Zanamivir 22,739 0.0034 895,204 5.6 6.6 12.1
Wisdom teeth Dominates 0.20 72,406 0.0 5.7 5.7
Table 4 Framework Matrix for Orlistat
ρ=0.504 Information
Implementation Current (in ) Perfect (in )
Current 82 82
Perfect 163 187
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value of the decision made purely on the basis of
this current information was estimated to be 99
(cell C), whereas the expected value of the decision
made on the basis of perfect information was esti-
mated to be 99 (cell D). Thus, the expected value of
perfect information was 0. With the current imple-
mentation level (rc) of 0.2, the realizable expected
value of the decision made on the basis of current
information was reduced to 20 (cell A). The
expected value of implementation and the expected
value of ‘‘perfection,’’ based on the current level of
information, were 79 per decision, 5:7 million for
the eligible population.
Sensitivity Analysis
Level of the cost-effectiveness threshold (l). Figures
1 and 2 illustrate the relationship between the value
of the cost-effectiveness threshold (l) and the popu-
lation values for EVPI, EVPIM, and EVP for orlistat
and zanamivir, respectively.
As the cost-effectiveness threshold approaches
the incremental cost-effectiveness ratio (ICER), the
uncertainty surrounding the decision to implement
the technology reaches a maximum, the incremental
net benefit approaches 0 (the decision maker is indif-
ferent between the 2 technologies), and the level of
perfect implementation is in transition (from 0 to 1).
As a result, the EVPI is large (although not necessa-
rily at a maximum), the EVPIM is close to 0, and the
EVP is close to the EVPI.
For values of l up to the ICER, the error probabil-
ity (reflected by the cost-effectiveness acceptability
curve30—not shown) and the value of the conse-
quences of an error are both increasing with l.
Hence, the EVPI must also increase (as illustrated in
Figures 1 and 2). Beyond this point, the error prob-
ability falls, whereas the value of the consequences
continues to rise along with the cost-effectiveness
threshold. Here, for both orlistat and zanamivir, the
fall in the error probability outweighs the rise in the
value of the consequences, and EVPI falls for values
of l beyond the ICER, but this need not be the case.
The EVPIM has the inverse relationship with the
Table 5 Framework Matrix for Zanamivir
ρ=0.0034 Information
Implementation Current (in ) Perfect (in )
Current 0.02 0.02
Perfect 7 14
Table 6 Framework Matrix for Wisdom Teeth
ρ=0.20 Information
Implementation Current (in ) Perfect (in )
Current 20 20
Perfect 99 99
ICER = £21,267
EVPIM
EVP
EVPI
Figure 1 Expected value of information, implementation, and
perfection for orlistat. EVPI, expected value of perfect information;
EVPIM, expected value of perfect implementation; EVP, expected
value of ‘‘perfection’’; ICER, incremental cost-effectiveness ratio.
ICER = £22,739
EVPI
EVP
EVPIM
Figure 2 Expected value of information, implementation, and per-
fection for zanamivir. EVPI, expected value of perfect information;
EVPIM, expected value of perfect implementation; EVP, expected
value of ‘‘perfection’’; ICER, incremental cost-effectiveness ratio.
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cost-effectiveness threshold, reaching a minimum at
the point where the cost-effectiveness threshold is
equal to the ICER (incremental net benefit [INB] is
0). At this point, the decision maker is indifferent
about whether to adopt the technology, and strate-
gies to change implementation between the old and
new technology will have no value. The behavior of
the EVPIM curve for values of l above and below
the ICER will depend on the interaction between the
perfect and current levels of implementation. For
values of the cost-effectiveness threshold below the
ICER, the optimal decision is not to provide the
technology (perfect level of implementation is 0).
However, for orlistat (Figure 1), the current level of
implementation exceeds 0. As such, strategies to
change implementation away from orlistat have
value (positive EVPIM). The value of such strategies
will fall as the cost-effectiveness threshold increases
toward the ICER and the negative impact of the cur-
rent implementation falls (INB rises toward 0). For
zanamivir (Figure 2), the current level of implemen-
tation (rc= 0:0034) is very close to the perfect level
of implementation (r=0). Thus, strategies to change
implementation away from zanamivir have negligi-
ble value.
When the cost-effectiveness threshold is above
the ICER, the optimal decision is to provide the tech-
nology (perfect level of implementation is 1). Given
that the current level of implementation is less than
1 (for both orlistat and zanamivir), strategies to
change implementation toward the technology will
have value (positive EVPIM). The value of such stra-
tegies will rise as the cost-effectiveness threshold
increases beyond the ICER and the negative impact
of the current implementation increases (INB rises).
Level of current implementation. Figure 3 examines
the impact that the current level of implementation
has on the expected values of perfect information,
perfect implementation, and perfection associ-
ated with orlistat. The figure is drawn for a cost-
effectiveness threshold of 30,000 per QALY, a
level at which orlistat is the most cost-effective
decision, and the optimal level of implementation
(r) is 1. When the current level of implementation
is 1, the expected value of perfect implementation
will be 0 as all patients are already receiving orli-
stat. When the current level of implementation is
0, the expected value of perfect implementation is
13:6 million. As the current level of implementa-
tion increases from 0 to 1, the expected value of
perfect implementation falls as a larger propor-
tion of patients receive orlistat and strategies to
change implementation have less value. The EVPI
is constant irrespective of the level of current
implementation as the calculation is made on the
assumption of perfect implementation. The EVP
falls as the proportion of current implementation
rises over the range from 0 to 1.
If the cost-effectiveness threshold were taken
to be 20,000 (not shown), orlistat would not be
cost-effective, the optimal level of implementation
would be 0, and the graph would be reversed, with
the expected value of implementation and the EVP
rising as the level of current implementation rises.
Revising the level of current implementation in res-
ponse to information. The initial analyses were
undertaken on the basis of a simplifying assumption
that information alone did not affect the level of
implementation, which could only be influenced by
implementation strategies (i.e., there was no relation-
ship between the level of information and the level of
implementation). Under this assumption, the expec-
ted value of perfect information achievable without
implementation policies (realizable EVPI) is 0. How-
ever, it is likely that the provision of information
would alter the level of implementation to some
extent independent of implementation effort.
Figure 4 illustrates how the value of the realiz-
able EVPI is affected by relaxing the simplifying
assumption and allowing the level of implementa-
tion to change on the basis of information alone
(rp 6¼ rc). The figure is drawn for orlistat and a cost-
effectiveness threshold of 30,000 per QALY, a level
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Figure 3 Sensitivity analysis on current implementation
proportion—orlistat. EVPI, expected value of perfect information;
EVPIM, expected value of perfect implementation; EVP, expected
value of ‘‘perfection.’’
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at which orlistat is the most cost-effective decision
and the optimal level of implementation (r) is 1.
When the level of implementation following the
information is 1 (perfect implementation), the real-
izable EVPI equals the EVPI. When the level of
implementation following the information is equal
to the current level (the information has no effect on
implementation), the realizable EVPI is 0. When the
level of implementation following the information is
above the current level, the information has increased
implementation in the desired direction (positive
impact), and the realizable EVPI is positive. When the
level of implementation following the information
is below the current level, the realizable EVPI is
negative. In this situation, the information has had a
negative impact on implementation, reducing imple-
mentation away from the desired level. The EVPI,
EVPIM, and EVP are all constant irrespective of the
postinformation implementation level (rp) because
they are calculated with respect to the proportion of
current implementation and/or the value of perfect
implementation.
If the cost-effectiveness threshold were taken to
be 20,000 (not shown), orlistat would not be cost-
effective, and the optimal level of implementation
would be 0. In this case, the realizable EVPI would
have the inverse relationship, with the postinforma-
tion level falling as the level of postinformation
implementation increased from 0 to 1. In this circum-
stance, the realizable EVPI would reach a maximum
(equal to EVPI) when the level of postinformation
implementation is 0 and would be negative when the
level of implementation postinformation exceeded
the current level of implementation.
DISCUSSION
The Results of the Case Studies
The results of the case studies have shown that the
value associated with funding further research and/or
strategies for changing implementation will differ
markedly between technologies. In the case of orlistat,
more value was associated with strategies to change
implementation (EVPIM= 6:8 million) than was
associated with further research (EVPI= 2 million),
although both were potentially worthwhile assuming
the cost of investment in either activity was less than
the value indicated. With zanamivir, the value asso-
ciated with further research (EVPI= 5:6 million) was
equivalent to the value associated with strategies to
change implementation (EVPIM= 6:6 million).
Again, assuming that the costs associated with the
investments were below these values, both were
potentially worthwhile. In the case of prophylactic
extraction of wisdom teeth, the value of further
research was negligible, whereas the value associated
with strategies to change implementation was substan-
tial (EVPIM= 5:7 million). In this case, the cost of
investing in further research would exceed the poten-
tial value of such investment, and no funding should
be allocated for further research. Instead, assuming that
the cost of strategies to improve implementation is
lower than the potential value associated with chan-
ging practice (5:7 million), funding effort should be
focused on strategies to reduce the number of prophy-
lacticwisdom teeth extractions that are performed.
Key Factors
Several key factors affect the expected values of
perfect information, perfect implementation, and
perfection, which in turn influence the allocation of
funds between service provision, further research,
and implementation strategies. These include the
following:
i) The level of the cost-effectiveness threshold (l). As
discussed above, the calculations of the expected
values of perfect information, perfect implementa-
tion, and perfection all depend on the value of the
cost-effectiveness threshold (l). This is due to the
interaction between the cost-effectiveness threshold
and i) the uncertainty surrounding the decision (see
below), ii) the extent of the net benefits (see below),
and iii) the level of perfect implementation.
ii) The uncertainty surrounding the adoption deci-
sion. The uncertainty surrounding the adoption
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Figure 4 Sensitivity analysis on postinformation implementa-
tion proportion for orlistat. EVPI, expected value of perfect infor-
mation; EVPIM, expected value of perfect implementation; EVP,
expected value of ‘‘perfection.’’
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decision is a crucial element in the calculation of
the expected value of perfect information, with the
EVPI increasing with increased uncertainty. Where
the uncertainty surrounding the decision is low
(e.g., prophylactic extraction of wisdom teeth), the
EVPI is negligible (0:02, not shown).
iii) The extent of the expected INB. The calculation of
the expected values of perfect information, perfect
implementation, and perfection is affected by the
extent of the expected INB. Where the INB are
small, the returns available from research and stra-
tegies aimed at improving implementation are
small. As such, the EVPI and EVPIM are small. For
example, the INB associated with zanamivir were
less than those associated with orlistat (7 com-
pared to 81); this affected the value of information
and implementation strategies (at the decision
level), which were lower for zanamivir (6 and 7
compared with 24 and 81, respectively).
iv) The current level of implementation. As illust-
rated in Figure 3, the calculations of the expected
values of perfect implementation and perfection
are both affected by the current level of implemen-
tation. Where the current level is close to the per-
fect level, the EVPIM is negligible. For example,
given a cost-effectiveness threshold of 20,000 per
QALY, the current level of implementation of
zanamivir (0.0034) was close to the perfect level
(0), and the EVPIM was negligible (0:01).
v) The size of the eligible population. The size of the
population eligible for treatment has a direct
impact on the population-level estimates of the
expected values of perfect information, perfect
implementation, and perfection. Where the popu-
lation is large, the scaled-up population values will
be large. For example, the population values of the
EVPI were larger for zanamivir than for orlistat
(5:6 million compared with 2 million) despite
lower values at the decision level (6 compared
with 24) due to the size of the estimated eligible
population (895k compared to 83k).
The allocation of funds between health care, research,
and implementation strategies will depend crucially
on these factors. As a result, policies regarding the
collection of further information and the funding of
strategies to improve implementation are likely to dif-
fer between technologies.
Future Developments of the Framework
This article has introduced a simple unified fra-
mework that sets out the necessary conditions for
assessing the value of implementation and the value
of information to address decisions concerning
health care funding allocations. A number of simpli-
fying assumptions have been made. For the frame-
work to have merit within decision making, these
simplifying assumptions must be relaxed and the
framework developed to incorporate these issues.
The proposed further development of the framework
examines the following issues:
i) The relationship between information and the cur-
rent level of implementation. The framework pre-
sented and applied to the case studies involved a
simplifying assumption that information alone had
no effect on the current level of implementation,
which is only influenced as a result of direct imple-
mentation strategies (i.e., there is no relationship
between information and implementation). Under
this assumption, the expected value of a decision
made with and without perfect information is
equivalent unless implementation strategies are
employed to change implementation (B=A). The
realizable EVPI is 0.
However, it is likely that the level of implementa-
tion is a function of the level of information and that
provision of information would alter the level of
implementation—for example, through publication
of the results of the research. It is important for the
framework to capture and incorporate this relation-
ship in order to appropriately value research efforts.
This will require formal assessment of the impact
that research has on the level of implementation. An
estimate of the relationship could be achieved via
investigation of historic implementation levels and
publication of research results or formal elicitation
of priors.
An initial sensitivity analysis illustrated the impact
of relaxing the assumption (Figure 4). Where informa-
tion led to a positive change in implementation
(a move toward the perfect level), the realizable EVPI
was positive, but where information led to a change
in implementation away from the perfect level
(a negative change), the realizable EVPI was negat-
ive. In this case, information reduced the expected
value of the decision. Negative changes of this type
may occur where the message from research gets con-
fused or interpreted inappropriately, or where clini-
cal practitioners do not base their decisions on cost-
effectiveness. For example, research that strengthens
the evidence about a technology’s positive effective-
ness may lead to increased implementation despite
evidence that shows it not to be cost-effective.
When formalizing and incorporating the relationship
between information and implementation within the
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framework, it will be important to consider both the
positive and negative impacts of research.
ii) Uncertainty about the current level of implemen-
tation. It has been assumed that the current level of
implementation was fixed and known. The level of
implementation, like all parameters in the model, is
subject to uncertainty, which should be captured
within the model. It is only by incorporating the
uncertainty around the current level of implementa-
tion within the model that it is possible to establish
the expected value of information about the level of
implementation (i.e., whether research to get a bet-
ter estimate of the current level of implementation is
worthwhile).
iii) Valuation of specific implementation strategies.
The framework presented within this article was
restricted to consider only 2 circumstances with
respect to the level of information and implemen-
tation: 1) the current level and 2) the perfect level.
The framework described a very simple 4-state
world (illustrated through a 2× 2 matrix) that
enabled calculation of the value of further research
that shifts the state of information from the current
level to the perfect level (EVPI), as well as the
value of implementation strategies that shift the
level of implementation from current to perfect
(EVPIM). These values establish a maximum re-
turn to investment within the area (implementa-
tion or information) and provide a necessary
condition for determining whether the investment
is potentially worthwhile.
To determine whether specific implementation
strategies are worthwhile, it is necessary to value
improvements in implementation that are achiev-
able, rather than perfect implementation. Calculation
of the expected value of specific implementation
(EVSIM) will involve determining the change in
implementation levels resulting from specific imple-
mentation strategies and computing the expected
value of those changes. It is only through comparison
of the EVSIM with the cost of the specific implemen-
tation strategies that it is possible to determine
whether it is worthwhile employing the strategies.
The concept is similar to that of the expected value of
sample information (EVSI) used to determine the
value and worth of information available from speci-
fic research.
Incorporating the EVSIM within the framework
will require a movement away from the simple 4-state
world, to include a situation of ‘‘improved’’ imple-
mentation. Current and recent studies examining
the cost-effectiveness of implementation strategies
could provide information about the effectiveness
of different strategies in achieving ‘‘improved’’
implementation.
The Next Steps with the Framework
In addition to developing the theoretical founda-
tions of the framework and relaxing the simplify-
ing assumptions, a series of steps must be taken to
demonstrate and establish the practical significance
and merit of the framework for decision makers. The
initial stage in this process would involve the pro-
spective application of the framework within an
ongoing technology appraisal, before the framework
is piloted prospectively as part of the NICE process.
CONCLUSIONS
In a budget-constrained health care system, deci-
sions regarding investment in implementation stra-
tegies must be made alongside those regarding
investment in health care services and further re-
search. We present a simple, unified framework
that examines the value of information and the
value of implementation simultaneously. Policy
makers can compare these maximum returns to
investment with the costs of investment in each
area to inform policy decisions about the allocation
of funds between these activities.
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